WISER-P: Real-world testing of software for measuring bone disease on whole-body MRI in patients with prostate cancer
Disease Site: Prostate cancer
Treatment Modality: Imaging
Status: In set-up
WISER-P is a prospective, randomised, multi-centre, controlled trial comparing the clinical performance of whole-body MRI (WBMRI), used with novel software, and conventional imaging (CT & bone scan), to assess treatment response of bone disease in patients with bone predominant metastatic castration resistant prostate cancer (mCRPC).
126 patients will be recruited from 8-10 UK sites over an 18 month period. All patients will undergo imaging, according to their randomised group, prior to commencement of systemic treatment and again at 8-9 weeks from start of treatment and patients will be followed up for a minimum 12 months from start of treatment.
Chief Investigator: Professor Dow-Mu Koh. The Royal Marsden NHS Trust.
ICR-CTSU Scientific Lead: Dr Nuria Porta
Trial Management Contact: [email protected]
Sponsor: The Institute of Cancer Research
Funding: National Institute for Health Research i4i (Invention for Innovation) Challenge Award
View WISER-P on the National Institute for Health Research website: NIHR - Be Part Of Research.
A lay summary in plain English will soon be available from Cancer Research UK.
Publications and Presentations
There have been no presentations or publications to date.